Tetra Natural Health Looking to Exploit Consumer Appetite for Hemp Based products
OTTAWA, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.
“We are thrilled in having signed this agreement with Kombucha Baby and its distribution partners providing Tetra Natural Health with access to a significant number of retail outlets in both Canada and the USA,” stated Richard Giguere, CEO of Tetra Natural Health.
“We are very excited to be adding the Hemp Energy Drink to our portfolio of products that will be available to our existing and potential client base,” stated Dan McKenna, President and CEO of Kombucha Baby Brewing Company Inc. “Numerous Canadian and U.S. customers representing thousands of retail outlets have indicated a strong interest in carrying this unique Natural Health Product (NHP).”
About
Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking
statements
Some
statements
in
this
release
may
contain
forward-looking
information.
All
statements,
other
than
of
historical
fact,
that
address
activities,
events
or
developments
that
the
Company
believes,
expects
or
anticipates
will
or
may
occur
in
the
future
(including,
without
limitation,
statements
regarding
potential
acquisitions
and
financings)
are
forward-looking
statements.
Forward-looking
statements
are
generally
identifiable
by
use
of
the
words
"may",
"will",
"should",
"continue",
"expect",
"anticipate",
"estimate",
"believe",
"intend",
"plan"
or
"project"
or the
negative
of
these
words
or
other
variations
on
these
words
or
comparable
terminology.
Forward-looking
statements
are
subject
to
a
number
of
risks
and
uncertainties,
many
of
which
are
beyond
the
Company's
ability
to
control
or
predict,
that
may cause
the
actual results
of
the
Company
to
differ
materially
from
those
discussed
in
the
forward-looking
statements.
Factors
that
could
cause
actual
results
or
events
to
differ
materially
from
current
expectations
include,
among
other
things,
without
limitation,
the
inability
of
the
Company
to
obtain
sufficient
financing
to
execute
the
Company's
business
plan;
competition;
regulation
and
anticipated
and
unanticipated costs
and
delays,
the
success
of
the
Company's
research
and
development
strategies,
including
this
trial,
the
ability
to
obtain
orphan
drug
status,
the
applicability
of
the
discoveries
made
therein,
the
successful
and
timely
completion
and
uncertainties
related
to
the
regulatory
process,
the
timing
of
clinical
trials,
the
timing
and
outcomes
of
regulatory
or
intellectual
property
decisions,
the
success
of
various
product
launches
including
the
one
discussed
in
this
release,
and
other
risks
disclosed
in
the
Company's
public
disclosure
record
on
file
with
the
relevant
securities
regulatory
authorities.
Although
the
Company
has
attempted
to
identify
important
factors
that
could
cause
actual
results
or
events
to
differ
materially
from
those
described
in
forward-looking
statements,
there
may
be
other
factors
that
cause
results
or
events
not
to
be
as
anticipated,
estimated
or
intended.
Readers
should
not
place
undue
reliance
on
forward-looking
statements.
While
no
definitive
documentation
has
yet
been
signed
by
the
parties
and
there
is
no
certainty
that
such
documentation
will
be
signed.
The
forward-looking
statements
included
in
this
news
release
are
made
as
of the
date
of this
news
release
and
the
Company
does
not
undertake
an
obligation
to
publicly
update
such
forward-looking
statements
to
reflect
new
information,
subsequent
events
or
otherwise
unless
required
by
applicable
securities
legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226
Carol.levine@energipr.com
Stephanie Engel
416-425-9143 ext. 209
Stephanie.engel@energipr.com
Source: Tetra Bio-Pharma Inc